Alzheimer's Disease Trial, Not Yet Recruiting NCT02438202 Sponsor: Central Institute of Mental Health, Mannheim Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT02438202
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with Alzheimer's disease according to standard psychiatric diagnostic guidelines, with a memory and thinking test score between 5 and 25 out of 30.
  • People who are already receiving standard Alzheimer's disease treatment as recommended by German national medical guidelines.
  • People who are able to give their own consent to participate, or who have a legal guardian who can consent on their behalf if the person is not able to do so themselves — a separate psychiatrist (not connected to the study) must confirm if there is any doubt about a person's ability to consent, and the treatment will never be carried out against the person's wishes.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a medical reason why they cannot safely receive electroconvulsive therapy (ECT) (confirm with trial site for specific details).
  • People who are currently experiencing a major depressive episode, as defined by standard psychiatric diagnostic guidelines.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 18 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alexander Sartorius, MD, PhD, Department of Psychiatry and Psychotherapy, Central Institute of Mental Health (CIMH), Medical Faculty Mannheim, University of Heidelberg

Phone: +49-621-1703

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Central Institute of Mental Health, Mannheim
Registry
ClinicalTrials.gov
Start date
1 December 2026
Est. completion
1 January 2028

Primary endpoints

Change in Cognition

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 18 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov